American Diabetes Association Strongly Advises Patients Using Rosiglitazone to See Their Doctor
Posted on: Wednesday, 6 June 2007, 18:00 CDT
ALEXANDRIA, Va., June 6 /PRNewswire-USNewswire/ -- On June 5, 2007, the New England Journal of Medicine published results of an interim analysis of the cardiovascular safety trial of rosiglitazone (brand name, Avandia). The article was accompanied by three editorials. Although the findings from RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes) found no significant increase in heart attack or cardiac death, but an increased risk of heart failure, this interim analysis did not have the statistical power to reach a definitive answer as to all the potential cardiovascular risks that may be associated with rosiglitazone. As one of the accompanying editorials stated, the RECORD study demonstrated a trend toward increased cardiovascular events and, when combined with recently published data and an analysis released by the company, there is still concern about cardiovascular side effects related to this drug.
As a result of all of this information, the American Diabetes Association strongly encourages patients taking this medication to consult with their physician as to its benefits and risks. The Association also reminds patients, however, that they should not stop taking any prescribed medications without first discussing the issue with their health care provider.
The most life-threatening consequences of diabetes are heart disease and stroke, which strike people with diabetes more than twice as often as they do others. If you have diabetes, it is very important to control your blood glucose, blood pressure and cholesterol levels.
The American Diabetes Association is the nation's leading voluntary health organization supporting diabetes research, information and advocacy. The Association's mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. Founded in 1940, the Association provides service to hundreds of communities across the country. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342- 2383) or visit http://www.diabetes.org/. Information from both these sources is available in English and Spanish.
To review the recent articles published by the New England Journal of Medicine, visit http://www.nejm.org/.
American Diabetes Association
CONTACT: Diane Tuncer of the American Diabetes Association,+1-703-549-1500 ext. 5510, dtuncer@diabetes.org
Web site: http://www.diabetes.org/
Source: PRNewswire-USNewswire
Related Articles
- Innovation Would Be the Best Method to Fight Generics' Primacy in the Latin American Cardiovascular Drugs Markets
- Endocrinology Panel Examines Interplay Between Diabetes and Cardiovascular Disease in New Report
- Diabetes Drug to Warn of Risk to Heart
- Study Reports Point-of-Care Test to Be As Accurate As Conventional Laboratory Analysis in Detecting Kidney Disease in Patients With Diabetes and Cardiovascular Disease
- The Combined Impact of Obesity, Diabetes, and Cardiovascular Disease is the World's Biggest Health Problem Today
- Optimizing Treatment of Diabetes and Cardiovascular Disease With Combined [Alpha],[Beta]-Blockade
- Obesity, Inactivity, and the Prevalence of Diabetes and Diabetes- Related Cardiovascular Comorbidities in the U.S., 2000-2002
- Diabetes and Cardiovascular Risk Markers
- New Book Explains Why Exercise Is Essential to Reversing Type 2 Diabetes and Cardiovascular Disease; Photo Available
- Is Lipid-Lowering Therapy Underused By African Americans at High Risk of Coronary Heart Disease Within the VA Health Care System?
 |
 |
User Comments (0)
RSS Feeds